8,420 Shares in Bio-Techne Corp (TECH) Acquired by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. acquired a new position in Bio-Techne Corp (NASDAQ:TECH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 8,420 shares of the biotechnology company’s stock, valued at approximately $1,018,000.

A number of other hedge funds also recently bought and sold shares of TECH. Teachers Advisors LLC raised its position in Bio-Techne Corp by 13.0% in the 1st quarter. Teachers Advisors LLC now owns 58,744 shares of the biotechnology company’s stock worth $5,971,000 after purchasing an additional 6,743 shares during the last quarter. Legal & General Group Plc raised its position in Bio-Techne Corp by 123.0% in the 1st quarter. Legal & General Group Plc now owns 24,288 shares of the biotechnology company’s stock worth $2,468,000 after purchasing an additional 13,398 shares during the last quarter. Thrivent Financial For Lutherans raised its position in Bio-Techne Corp by 9.6% in the 1st quarter. Thrivent Financial For Lutherans now owns 7,330 shares of the biotechnology company’s stock worth $746,000 after purchasing an additional 640 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Bio-Techne Corp by 4.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 188,094 shares of the biotechnology company’s stock worth $19,119,000 after purchasing an additional 7,889 shares during the last quarter. Finally, Morgan Stanley raised its position in Bio-Techne Corp by 5.9% in the 1st quarter. Morgan Stanley now owns 90,126 shares of the biotechnology company’s stock worth $9,162,000 after purchasing an additional 4,988 shares during the last quarter. Hedge funds and other institutional investors own 98.66% of the company’s stock.

TECH has been the subject of several research analyst reports. Deutsche Bank AG set a $132.00 price objective on shares of Bio-Techne Corp and gave the stock a “buy” rating in a research report on Wednesday, August 30th. Zacks Investment Research upgraded shares of Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $136.00 price objective for the company in a research report on Wednesday, October 11th. BidaskClub cut shares of Bio-Techne Corp from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Citigroup Inc. restated a “buy” rating and issued a $115.00 price objective (down previously from $125.00) on shares of Bio-Techne Corp in a research report on Tuesday, October 24th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Bio-Techne Corp presently has a consensus rating of “Buy” and a consensus price target of $134.33.

ILLEGAL ACTIVITY WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/11/11/8420-shares-in-bio-techne-corp-tech-acquired-by-crossmark-global-holdings-inc.html.

In other Bio-Techne Corp news, Director Robert V. Baumgartner sold 5,000 shares of Bio-Techne Corp stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $130.18, for a total transaction of $650,900.00. Following the completion of the sale, the director now owns 12,712 shares of the company’s stock, valued at approximately $1,654,848.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Karen A. Holbrook sold 1,059 shares of Bio-Techne Corp stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $121.73, for a total transaction of $128,912.07. Following the sale, the director now directly owns 914 shares of the company’s stock, valued at approximately $111,261.22. The disclosure for this sale can be found here. Insiders have sold a total of 6,259 shares of company stock valued at $804,102 in the last ninety days. Company insiders own 3.40% of the company’s stock.

Shares of Bio-Techne Corp (TECH) opened at $124.24 on Friday. The company has a current ratio of 2.87, a quick ratio of 2.25 and a debt-to-equity ratio of 0.35. Bio-Techne Corp has a fifty-two week low of $95.68 and a fifty-two week high of $132.57. The company has a market cap of $4,671.53, a price-to-earnings ratio of 35.94, a price-to-earnings-growth ratio of 3.11 and a beta of 0.74.

Bio-Techne Corp (NASDAQ:TECH) last released its earnings results on Tuesday, October 31st. The biotechnology company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.08. Bio-Techne Corp had a net margin of 12.54% and a return on equity of 14.11%. The firm had revenue of $144.61 million during the quarter, compared to analyst estimates of $142.37 million. During the same quarter in the previous year, the business earned $0.84 EPS. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. equities analysts forecast that Bio-Techne Corp will post 3.76 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 24th. Shareholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 1.03%. The ex-dividend date is Thursday, November 9th. Bio-Techne Corp’s dividend payout ratio is presently 66.32%.

Bio-Techne Corp Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Institutional Ownership by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply